文献速递浆细胞疾病

中期细胞遗传学与浆细胞增殖指数在新诊断多发性骨髓瘤风险分层中的作用

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
PubMed 文献 · Blood Adv · 2020-01-01

该回顾性队列研究纳入483例接受蛋白酶体抑制剂和/或免疫调节剂治疗的新诊断多发性骨髓瘤患者,评估中期细胞遗传学异常、浆细胞增殖指数(PCPro)及FISH 1q获得在修订版国际分期系统(R-ISS)和年龄基础上的风险分层价值。多变量分析显示上述指标均与较差的无进展生存(PFS)和总生存(OS)相关,但加入风险评分系统后并未改善对PFS或OS的Kaplan-Meier估计的风险判别能力,也未改善Uno删失校正C统计量的预后性能。配对分析显示中期细胞遗传学对预后染色体异常的检测不敏感。

要点

  • R-ISS、年龄、中期细胞遗传学异常、PCPro和FISH 1q获得均与较差PFS和OS相关。
  • 将中期细胞遗传学异常、PCPro和FISH 1q获得加入包含R-ISS和年龄的风险评分系统未改善PFS或OS的风险判别。
  • 中期细胞遗传学对预后染色体异常的检测不敏感,与PCPro和FISH 1q获得均未改善风险分层。

核心结论

  • 在考虑R-ISS和年龄的情况下,中期细胞遗传学、PCPro和FISH 1q获得未改善新诊断多发性骨髓瘤的风险分层。
  • 中期细胞遗传学对重要染色体异常的检测缺乏敏感性。

研究设计与样本

  • 回顾性队列研究,纳入483例接受蛋白酶体抑制剂和/或免疫调节剂治疗的新诊断多发性骨髓瘤患者。

主要发现

  • 多变量分析显示R-ISS、年龄、中期细胞遗传学异常(总体及特定异常)、PCPro和FISH 1q获得均与较差的无进展生存(PFS)和总生存(OS)相关。
  • 基于多变量分析风险比构建风险评分系统,将患者分为低、中、高危组;将中期细胞遗传学异常、PCPro和FISH 1q获得加入包含R-ISS和年龄的风险评分系统未改善PFS或OS的Kaplan-Meier估计的风险判别。
  • 通过Uno删失校正C统计量评估,上述指标未改善预后性能。
  • 配对分析显示中期细胞遗传学对预后染色体异常的检测不敏感。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metaphase cytogenetic abnormalities, plasma cell proliferation index (PCPro), and gain 1q by fluorescence in situ hybridization (FISH) are associated with inferior survival in newly diagnosed multiple myeloma (MM) treated with novel agents; however, their role in risk stratification is unclear in the era of the revised International Staging System (R-ISS). The objective of this study was to determine if these predictors improve risk stratification in newly diagnosed MM when accounting for R-ISS and age. We studied a retrospective cohort of 483 patients with newly diagnosed MM treated with proteasome inhibitors and/or immunomodulators. On multivariable analysis, R-ISS, age, metaphase cytogenetic abnormalities (both in aggregate and for specific abnormalities), PCPro, and FISH gain 1q were associated with inferior progression-free (PFS) and overall survival (OS). We devised a risk scoring system based on hazard ratios from multivariable analyses and assigned patients to low-, intermediate-, and high-risk groups based on their cumulative scores. The addition of metaphase cytogenetic abnormalities, PCPro, and FISH gain 1q to a risk scoring system accounting for R-ISS and age did not improve risk discrimination of Kaplan-Meier estimates for PFS or OS. Moreover, they did not improve prognostic performance when evaluated by Uno's censoring-adjusted C-statistic. Lastly, we performed a paired analysis of metaphase cytogenetic and interphase FISH abnormalities, which revealed the former to be insensitive for the detection of prognostic chromosomal abnormalities. Ultimately, metaphase cytogenetics lack sensitivity for important chromosomal aberrations and, along with PCPro and FISH gain 1q, do not improve risk stratification in MM when accounting for R-ISS and age.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Mellors PW, Binder M, Ketterling RP, et al. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. Blood Adv. 2020. PMID: 32442300. doi:10.1182/bloodadvances.2019001275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。